Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia

By Lundin Jeanette   Karlsson Claes   Celsing Fredrik  

Medical Oncology, Vol. 23, Iss. 1, 2006-03 ,pp. : 137-139

Humana Press, Inc

Access to resources Recommend Favorite

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

By Ogura Michinori   Hatake Kiyohiko   Tobinai Kensei   Uchida Toshiki   Suzuki Tatsuya   Terui Yasuhito   Yokoyama Masahiro   Maruyama Dai   Mori Masakazu   Jewell Roxanne C.   Katsura Koichi   Hotta Tomomitsu  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 5, 2013-05 ,pp. : 466-475

Oxford University Press

Access to resources Recommend Favorite

High-Risk Fludarabine-Pretreated B-Cell Chronic Lymphocytic Leukemia’s High Response Rate Following Sequential DHAP and Alemtuzumab Administration Though in Absence of Molecular Remission

By  

Medical Oncology, Vol. 23, Iss. 3, 2006-09 ,pp. : 359-368

Humana Press, Inc

Access to resources Recommend Favorite

Alemtuzumab in chronic lymphocytic leukemia

By James Danelle F   Kipps Thomas J  

Future Oncology, Vol. 3, Iss. 1, 2007-02 ,pp. : 29-42

Future Medicine

Access to resources Recommend Favorite

Monoclonal antibodies in the treatment of chronic lymphocytic leukemia

By Liu Nina   O’Brien Susan  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 297-304

Humana Press, Inc

Access to resources Recommend Favorite